These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6839004)

  • 21. Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals.
    Regårdh CG; Landahl S; Larsson M; Lundborg P; Steen B; Hoffmann KJ; Lagerström PO
    Eur J Clin Pharmacol; 1983; 24(2):221-6. PubMed ID: 6840171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics and absolute bioavailability of atenolol.
    Mason WD; Winer N; Kochak G; Cohen I; Bell R
    Clin Pharmacol Ther; 1979 Apr; 25(4):408-15. PubMed ID: 428185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single intravenous dose kinetics accumulation of atenolol in patients with impaired renal function and on hemodialysis.
    Kirch W; Schäfer M; Braun M
    Arch Toxicol Suppl; 1980; 4():366-9. PubMed ID: 6933939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rifampicin on metoprolol and antipyrine kinetics.
    Bennett PN; John VA; Whitmarsh VB
    Br J Clin Pharmacol; 1982 Mar; 13(3):387-91. PubMed ID: 7059439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.
    Kendall MJ; Jack DB; Laugher SJ; Lobo J; Rolf Smith S
    Br J Clin Pharmacol; 1984 Sep; 18(3):331-5. PubMed ID: 6487472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone.
    Riva E; Farina PL; Sega R; Tognoni G; Bastain W; McAinsh J
    Eur J Clin Pharmacol; 1980 May; 17(5):333-7. PubMed ID: 7418712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience with atenolol in patients with chronic liver disease.
    Kirch W; Schäfer-Korting M; Mutschler E; Ohnhaus EE; Braun W
    J Clin Pharmacol; 1983 Apr; 23(4):171-7. PubMed ID: 6863581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased oral clearance of metoprolol in pregnancy.
    Högstedt S; Lindberg B; Rane A
    Eur J Clin Pharmacol; 1983; 24(2):217-20. PubMed ID: 6840170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atenolol kinetics in renal failure.
    McAinsh J; Holmes BF; Smith S; Hood D; Warren D
    Clin Pharmacol Ther; 1980 Sep; 28(3):302-9. PubMed ID: 7408390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of atenolol and metoprolol administered together with piroxicam.
    Spahn H; Langguth P; Krauss D; Kirch W; Mutschler E
    Arch Pharm (Weinheim); 1987 Feb; 320(2):103-7. PubMed ID: 3579517
    [No Abstract]   [Full Text] [Related]  

  • 31. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.
    Fitzgerald JD; Ruffin R; Smedstad KG; Roberts R; McAinsh J
    Eur J Clin Pharmacol; 1978 May; 13(2):81-9. PubMed ID: 658112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol.
    Warrington SJ; Holt D; Johnston A; Fitzsimons TJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):37S-44S. PubMed ID: 6146339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.
    Freestone S; Silas JH; Lennard MS; Ramsay LE
    Br J Clin Pharmacol; 1982 Nov; 14(5):713-8. PubMed ID: 7138751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between the acute hemodynamic effects and brain penetration of atenolol and metoprolol.
    van Zwieten PA; Timmermans PB
    J Cardiovasc Pharmacol; 1979; 1(1):85-96. PubMed ID: 94385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.
    Lemmer B; Winkler H; Ohm T; Fink M
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):42-9. PubMed ID: 2864639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.
    Hoffmann KJ; Regårdh CG; Aurell M; Ervik M; Jordö L
    Clin Pharmacokinet; 1980; 5(2):181-91. PubMed ID: 7363533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atenolol interaction with aspirin, allopurinol, and ampicillin.
    Schäfer-Korting M; Kirch W; Axthelm T; Köhler H; Mutschler E
    Clin Pharmacol Ther; 1983 Mar; 33(3):283-8. PubMed ID: 6825385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
    Lennard MS; Tucker GT; Silas JH; Woods HF
    Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of metoprolol.
    Regårdh CG; Johnsson G
    Clin Pharmacokinet; 1980; 5(6):557-69. PubMed ID: 7002420
    [No Abstract]   [Full Text] [Related]  

  • 40. Bioavailability of atenolol formulations.
    Mcainsh J; Simpson WT; Holmes BF; Young J; Ellis SH
    Biopharm Drug Dispos; 1980; 1(6):323-32. PubMed ID: 7459427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.